As the show gets ready to open up for its final day, it certainly sets a proper stage from which to look both backwards and forwards. Beyond the normal prep work that goes into covering an event such as IPCPR, my week began with a seminar on the FDA and legislative issues that didn’t offer the kind of attendance that I expected or hoped to see. I know IPCPR is often seen as a celebration, it’s Las Vegas, etc. But this is the FDA we are talking about, and they have two options on the table, one of which will be implemented at some point–possibly even before next year’s trade show–and it seemed like too many people had other things to do than learn about how the industry that is the reason for this event could be effected and how to step up and join the fight against it. On the show floor, I didn’t get the clear and concise vibe about whether the pending FDA regulation was affecting buying or selling. Certainly retailers have to keep their shelves filled and manufacturers aren’t going to fold up shop, but beyond that it just didn’t seem clear, especially for what could be ...
↧